

GlycoMimetics Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 19-Jan-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 13

Product Portfolio Drugs..... 17

[Return to Table of Contents](#)

GlycoMimetics Inc

COMPANY OVERVIEW

Company Name	GlycoMimetics Inc
Parent Company Name	GlycoMimetics Inc
Website	http://www.glycomimetics.com/
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	2
Number of Patents as Owner	24
Number of Patents as Third Party	0
Number of Deals	7
Key Indications	Inflammatory disease,Cancer,Acute myelogenous leukemia,Hematological neoplasm,Thromboembolism,Cardiovascular disease,Deep vein thrombosis,Metastasis,Pancreas tumor,Pseudomonas aeruginosa infection,Sickle cell crisis
Key Target-based Actions	E-Selectin antagonist,Cell adhesion molecule inhibitor,P-Selectin antagonist,CXCR4 chemokine antagonist,L-Selectin antagonist,Dendritic ICAM-3 grabbing nonintegrin 1 inhibitor,Selectin modulator,Unspecified cell adhesion molecule inhibitor
Key Technologies	Small molecule therapeutic,Intravenous formulation,Oral formulation,Biological therapeutic,Infusion,Nasal systemic formulation,Subcutaneous formulation,Peptidomimetic

COMPANY PROFILE

SUMMARY

GlycoMimetics Inc (GMI) is active in the field of glycobiology and develops small-molecule drugs that mimic the functions of certain carbohydrates. The company's initial focus is on therapeutics to treat inflammatory diseases and cancer.

ACQUISITIONS AND SPIN-OFFS

By early 2003, GMI had acquired the assets of GlycoTech Corp, including exclusive rights to 15 issued US patents and numerous small molecules that could have therapeutic potential.

COMPANY LOCATION

In August 2014, the company's headquarters was shifted to Medical Center Drive in Rockville, Maryland.

FINANCIAL

In October 2013, GlycoMimetics filed a registration statement on Form S-1 with the US SEC for a proposed initial public offering of shares of its common stock. By that time, the company had applied to list its common stock on the NASDAQ Global Market under the ticker symbol 'GLYC'. In January 2014, the company priced the offering of 7,000,000 common stock shares at \$8.00 per share and granted a 30-day option to the underwriters to purchase up to an additional 1,050,000 common stock shares. At that time, the offering was expected to close on January 15, 2014; later that month, the offering of 8,050,000 shares was closed. The company raised net proceeds of approximately \$57.4 million.

In October 2009, GlycoMimetics raised \$38 million from a venture financing round.

In June 2006, GlycoMimetics raised an additional \$15.4 million from its series B financing. It planned to use the funds for preclinical development of its selectin inhibitors for inflammation and its lectin-binding glycomimetics for infection.

In August 2004, GlycoMimetics raised an additional \$5.1 million from an extension to a series A seed financing, bringing total proceeds to \$9.6 million. The funds would be used to advance the company's research programs.

[Return to Table of Contents](#)



In May 2003, GMI closed on its initial seed round of venture financing.

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	7.05
Change (USD)	0.13 (1.88%)
Previous Close Price (USD)	6.92
Volume	12,504
52-Week High (USD)	18.99
52-Week Low (USD)	6.02
Date	16-Jan-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	18,894,742
Current Market Capitalization	133,207,931
EPS (Date Reported)	-0.42

[Return to Table of Contents](#)

STOCK PERFORMANCE



MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Franklin Templeton Invest-Biotechnology Discovery	Mutual Fund	United States	554,885	2.94	-180,800	-0.25	31-Oct-2014
Hartford Healthcare Fund	Mutual Fund	United States	347,307	1.84	2,520	0.01	30-Nov-2014
Candriam Belgium S.A.	Investment Advisor	Belgium	235,000	1.24	0	0	31-Oct-2014
Dexia Equities L Biotechnology	Mutual Fund	Belgium	235,000	1.24	0	0	31-Oct-2014
Hartford Healthcare HLS Fund	Mutual Fund	United States	131,300	0.69	0	0	30-Nov-2014
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	122,530	0.65	0	0	30-Nov-2014
Met Inv. Ser. Trust Blackrock Large-Cap Core Portf	Mutual Fund	United States	108,511	0.57	0	0	30-Nov-2014
Hartford SmallCap Growth Fund	Mutual Fund	United States	103,260	0.55	0	0	30-Nov-2014

[Return to Table of Contents](#)

Vanguard Extended Market Index Fund	Mutual Fund	United States	68,635	0.36	0	0	30-Nov-2014
USAA Science & Technology Fund	Mutual Fund	United States	56,504	0.3	660	0.01	30-Nov-2014
Hartford SmallCap Growth HLS Fund	Mutual Fund	United States	51,066	0.27	0	0	30-Nov-2014
NVIT Multi-Manager Small Cap Growth Fund	Mutual Fund	United States	43,910	0.23	0	0	30-Nov-2014
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	32,989	0.17	0	0	30-Nov-2014
Hartford Small Company HLS Fund, Inc.	Mutual Fund	United States	19,586	0.1	-3,330	-0.15	30-Nov-2014
iShares Micro-Cap ETF	Mutual Fund	United States	24,483	0.13	1,746	0.08	31-Dec-2014
Hartford Small Company Fund	Mutual Fund	United States	17,990	0.1	-3,210	-0.15	30-Nov-2014
Fidelity Spartan Total Market Index Fund	Mutual Fund	United States	10,456	0.06	0	0	30-Nov-2014
GuideMark Small/Mid Cap Core Fund	Mutual Fund	United States	11,345	0.06	0	0	31-Oct-2014
Fidelity NASDAQ Composite Index Fund	Mutual Fund	United States	2,640	0.01	0	0	30-Nov-2014
Vanguard US Equity Index Fund	Mutual Fund	United States	2,500	0.01	0	0	31-Oct-2014

[Return to Table of Contents](#)

FINANCIAL PERFORMANCE

Sales and Income



	2013	2012	2011		
Sales (USD M)	3.992649	15.257351	3.813913		
Operating Income (USD M)	-10.58872	3.661637	-6.084802		
Net Income (USD M)	-10.605586	3.656022	-6.113193		

Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q3	0	-6.699162	-6.617577
2014 Q2	15.027004	8.064216	7.991721
2014 Q1	0	-5.106623	-5.10185
2013 Q3	0.052571	-3.700901	-3.700885
2013 Q1	3.807592	0.458722	0.459687

BALANCE SHEET

[Return to Table of Contents](#)

Assets (USD M)

	2011	2012	2013		
Cash & Short Term Investments	28.172174	17.372832	2.310603		
Inventories - Total	0	0	0		
Current Assets - Total	28.366381	17.969013	4.883675		
Property, Plant And Equipment - Net	0.234502	0.450759	0.399799		
Other Assets - Total	0.308521	0	0		
Total Assets	28.909404	18.419772	5.283474		

Liabilities (USD M)

	2011	2012	2013		
Accounts Payable	0.535597	0.764195	1.144895		
Short Term Debt & Current Portion Of Long Term Debt			0		
Current Liabilities - Total	16.412225	5.691558	2.279299		
Long Term Debt	0	0	0		
Other Liabilities	4.040262	0.19983	0.096756		
Total Liabilities	20.452487	5.891388	2.376055		

Stockholders Equity (USD M)

	2011	2012	2013		
Minority Interest	0	0	0		
Preferred Stock	0.030726	0.030726	0.030726		
Common Stock	0.00093	0.00093	0.001428		
Treasury Stock		0			
Total Liabilities & Shareholders' Equity	28.909404	18.419772	5.283474		

FORECASTS

[Return to Table of Contents](#)

EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-0.46	-0.46	-1.43
31-Dec-2016	-0.94	-0.94	-0.14
31-Dec-2017	0.15	0.15	1.16

Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0		-8.8	26.03
31-Dec-2016	0		-17.96	26.5
31-Dec-2017			3.24	54.17


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	1	4
Hematological disease	3	0	3
Inflammatory disease	2	1	3
Immune disorder	0	2	2
Infectious disease	1	1	2
Cardiovascular disease	2	0	2
Respiratory disease	0	1	1
Gastrointestinal disease	1	0	1
Genetic disorder	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	1
Discovery	3
No Development Reported	2

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Patent - Exclusive Rights	0	0	1	0	1
Drug - Funding	1	0	0	0	1
Drug - Early Research/Development	1	0	0	0	1
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Development Services	0	0	3	0	3

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Hematological disease	1	3
Genetic disorder	0	2
Neoplasm	1	1

Trials by Phase

Phase	Ongoing	All
Phase 2	0	1
Phase 1	2	5

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)



PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	10	0	10
Endocrine disease	3	0	3
Gastrointestinal disease	4	0	4
Hematological disease	12	0	12
Degeneration	1	0	1
Immune disorder	10	0	10
Musculoskeletal disease	2	0	2
Neoplasm	12	0	12
Ocular disease	1	0	1
Genetic disorder	3	0	3
Metabolic disorder	3	0	3
Neurological disease	2	0	2
Respiratory disease	3	0	3
Infectious disease	7	0	7
Injury	2	0	2
Inflammatory disease	14	0	14
Dermatological disease	5	0	5
Ulcer	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

rivipansel sodium

Drug Name	rivipansel sodium
Key Synonyms	rivipansel sodium, rivipansel
Originator Company	GlycoMimetics Inc
Active Companies	GlycoMimetics Inc, Pfizer Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Sickle cell crisis
Target-based Actions	Cell adhesion molecule inhibitor, E-Selectin antagonist, L-Selectin antagonist, P-Selectin antagonist
Other Actions	Anti-inflammatory, Anticancer, Chemoprotectant, Platelet aggregation inhibitor
Technologies	Subcutaneous formulation, Intravenous formulation, Infusion, Small molecule therapeutic
Last Change Date	29-Dec-2014

GMI-1271

Drug Name	GMI-1271
Key Synonyms	
Originator Company	GlycoMimetics Inc
Active Companies	GlycoMimetics Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Deep vein thrombosis, Metastasis, Acute myelogenous leukemia, Pancreas tumor, Thromboembolism
Target-based Actions	E-Selectin antagonist
Other Actions	Anticancer, Synergist, Anti-inflammatory
Technologies	Oral formulation, Intravenous formulation, Small molecule therapeutic
Last Change Date	06-Jan-2015

[Return to Table of Contents](#)



GMI-1051

Drug Name	GMI-1051
Key Synonyms	
Originator Company	GlycoMimetics Inc
Active Companies	GlycoMimetics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Pseudomonas aeruginosa infection
Target-based Actions	
Other Actions	Unspecified drug target, Bacterial pathogenicity factor modulator, Antibacterial
Technologies	Nasal systemic formulation, Small molecule therapeutic
Last Change Date	12-Nov-2014

dual E-selectin and CXCR4 inhibitors (hematological cancer/inflammation), GlycoMimetics

Drug Name	dual E-selectin and CXCR4 inhibitors (hematological cancer/inflammation), GlycoMimetics
Key Synonyms	
Originator Company	GlycoMimetics Inc
Active Companies	GlycoMimetics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hematological neoplasm, Inflammatory disease
Target-based Actions	E-Selectin antagonist, Cell adhesion molecule inhibitor, CXCR4 chemokine antagonist
Other Actions	Anti-inflammatory, Anticancer chemosensitizer
Technologies	Small molecule therapeutic
Last Change Date	22-Jan-2014

[Return to Table of Contents](#)



E-selectin inhibitors (oral, inflammatory disease/cardiovascular disease/cancer), GlycoMimetics

Drug Name	E-selectin inhibitors (oral, inflammatory disease/cardiovascular disease/cancer), GlycoMimetics
Key Synonyms	
Originator Company	GlycoMimetics Inc
Active Companies	GlycoMimetics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer, Cardiovascular disease, Inflammatory disease
Target-based Actions	E-Selectin antagonist
Other Actions	Anticancer, Anti-inflammatory, Cardiovascular agent
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	21-Jan-2014

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

